Mereo BioPharma to Present at the Stifel 2020 Virtual Healthcare Conference
Mereo BioPharma Group, a clinical stage biopharmaceutical company, announced that CEO Dr. Denise Scots-Knight will present at the Stifel 2020 Virtual Healthcare Conference on November 16, 2020, at 11:20 am ET. Investors can access a live audio webcast via the company’s website, with an archived version available for two weeks after the event. Mereo focuses on oncology and rare diseases, with products like etigilimab and setrusumab currently in various clinical trials. Forward-looking statements in the announcement caution investors about potential risks and uncertainties.
- None.
- None.
LONDON and REDWOOD CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020 at 11:20am Eastern Time.
A live audio webcast of the presentation can be accessed through the Investors section of the company’s website at mereobiopharma.com/investors/results-reports-and-presentations. An archived replay of the webcast will be available on the company’s website for two weeks following the live presentation.
About Mereo BioPharma
Mereo BioPharma is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Mereo's lead oncology product candidate, etigilimab (Anti-TIGIT), has completed a Phase 1a dose escalation clinical trial in patients with advanced solid tumors and has been evaluated in a Phase 1b study in combination with nivolumab in select tumor types. Mereo's rare disease product portfolio consists of setrusumab, which has completed a Phase 2b dose-ranging study in adults with osteogenesis imperfecta (OI), as well as alvelestat, which is being investigated in a Phase 2 proof-of-concept clinical trial in patients with alpha-1 antitrypsin deficiency (AATD) and in a Phase 1b/2 clinical trial in COVID-19 respiratory disease.
Forward-Looking Statements
This Announcement contains "forward-looking statements." All statements other than statements of historical fact contained in this Announcement are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements usually relate to future events and anticipated revenues, earnings, cash flows or other aspects of our operations or operating results. Forward-looking statements are often identified by the words "believe," "expect," "anticipate," "plan," "intend," "foresee," "should," "would," "could," "may," "estimate," "outlook" and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company's current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates.
All of the Company's forward-looking statements involve known and unknown risks and uncertainties some of which are significant or beyond its control and involve assumptions that could cause actual results to differ materially from the Company's historical experience and its present expectations or projections. These forward-looking statements are subject to risks and uncertainties, including, among other things, those described in our Annual Report on Form 10-K for the year ended December 31, 2019 and subsequent Quarterly Reports on Form 10-Q under the caption “Risk Factors.” Other risks, uncertainties, and factors that could cause actual results to differ materially from those projected may be described from time to time in reports we file with the Securities and Exchange Commission, including reports on Forms 10-Q and 8-K. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
These forward-looking statements are subject to risks and uncertainties, including, among other things, those described in the Company’s latest Annual Report on Form 20-F, Reports on Form 6-K and other documents filed from time to time by the Company with the United States Securities and Exchange Commission. The Company wishes to caution investors not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.
Mereo BioPharma Contacts:
| Mereo | +44 (0)333 023 7300 |
| Denise Scots-Knight, Chief Executive Officer | |
| N+1 Singer (Nominated Adviser and Broker to Mereo) | +44 (0)20 7496 3081 |
| Phil Davies | |
| Will Goode | |
| Burns McClellan (US Investor Relations Adviser to Mereo) | +01 212 213 0006 |
| Lisa Burns | |
| Lee Roth | |
| FTI Consulting (UK Public Relations Adviser to Mereo) | +44 (0)20 3727 1000 |
| Simon Conway | |
| Ciara Martin | |
| Investors | investors@mereobiopharma.com |
FAQ
What is Mereo BioPharma presenting at the Stifel 2020 Virtual Healthcare Conference?
How can I access the Mereo BioPharma presentation?
What is the focus of Mereo BioPharma's research?
What products is Mereo BioPharma currently developing?
When will the archived version of Mereo BioPharma's presentation be available?
